Cancer Biomarkers Market Size, Share, Trends, Industry Analysis Report: By Type, Biomolecule, Application, and Region

Description

List of Tables

The cancer biomarkers market size is expected to reach USD 69.05 billion by 2034, according to a new study by Polaris Market Research. The report "Cancer Biomarkers Market Size, Share, Trends, Industry Analysis Report: By Type (Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, and Others), Biomolecule, Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The cancer biomarkers market growth is attributed to various factors such as the increasing prevalence of cancer across the world, advancements in genomic and proteomic technologies, and the rising demand for personalized medicine. Early detection and precision therapies are in high demand, leading to more focus on developing novel biomarkers for diagnosis, prognosis, and treatment monitoring. Key cancer biomarkers market trends include the growing adoption of noninvasive liquid biopsy methods, integration of artificial intelligence in biomarker discovery, and the expansion of companion diagnostics.

The market offers substantial opportunities for companies to innovate in areas such as targeted therapies and next-generation sequencing. As healthcare providers increasingly prioritize personalized cancer treatment, the market is expected to continue its expansion, with significant investments in research, collaborations, and technological advancements shaping its future growth.

Cancer Biomarkers Market Report Highlights

By type, the breast cancer segment holds the largest share of the cancer biomarkers market revenue due to its high prevalence and significant research investments in early detection and targeted therapies. The lung cancer segment is experiencing the highest growth, driven by advancements in noninvasive diagnostic methods and increasing incidence rates.

In terms of biomolecule, the genetic biomarkers segment dominates the market as they play a critical role in personalized treatment and genomic profiling for cancer detection. The proteomic biomarkers segment is registering the highest growth, with an increasing focus on protein-based diagnostics and therapy development.

The diagnostics segment, by application, leads the cancer biomarkers market share, driven by the rising demand for early cancer detection and continuous advancements in diagnostic technologies. The personalized medicine segment is the fastest-growing application, as it emphasizes tailored treatments based on individual genetic and molecular profiles.

North America holds the largest market share, fueled by the presence of advanced healthcare infrastructure, high cancer prevalence, and significant research investments. Asia Pacific is the fastest-growing region, with increasing cancer incidence, improving healthcare systems, and growing adoption of innovative diagnostic technologies.

Polaris Market Research has segmented the cancer biomarkers market report on the basis of type, biomolecule, application, and region

By Type Outlook (Revenue - USD Billion, 2020-2034)

Breast Cancer
Prostate Cancer
Colorectal Cancer
Cervical Cancer
Liver Cancer
Lung Cancer
Others

By Biomolecule Outlook (Revenue - USD Billion, 2020-2034)

Genetic Biomarkers
Epigenetic Biomarkers
Metabolic Biomarkers
Proteomic Biomarkers
Others

By Application Outlook (Revenue - USD Billion, 2020-2034)

Drug Discovery & Development
Diagnostics
Personalized Medicine
Others

By Regional Outlook (Revenue - USD Billion, 2020-2034)

North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America

Product Code: PM3738

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Source
- 3.2.1. Primary Source
- 3.2.2. Secondary Source

4. Global Cancer Biomarkers Market Insights

4.1. Cancer Biomarkers Market - Market Snapshot
4.2. Cancer Biomarkers Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Rising Prevalence of Cancer
  - 4.2.1.2. Advancements in Biomarker Discovery Technologies
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. High Cost and Complexity of Biomarker Validation and Clinical Trials
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Cancer Biomarkers Market Application Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Cancer Biomarkers Market, by Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
5.3. Breast Cancer
- 5.3.1. Global Cancer Biomarkers Market, by Breast Cancer, by Region, 2020-2034 (USD Billion)
5.4. Prostate Cancer
- 5.4.1. Global Cancer Biomarkers Market, by Prostate Cancer, by Region, 2020-2034 (USD Billion)
5.5. Colorectal Cancer
- 5.5.1. Global Cancer Biomarkers Market, by Colorectal Cancer, by Region, 2020-2034 (USD Billion)
5.6. Cervical Cancer
- 5.6.1. Global Cancer Biomarkers Market, by Cervical Cancer, by Region, 2020-2034 (USD Billion)
5.7. Liver Cancer
- 5.7.1. Global Cancer Biomarkers Market, by Liver Cancer, by Region, 2020-2034 (USD Billion)
5.8. Lung Cancer
- 5.8.1. Global Cancer Biomarkers Market, by Lung Cancer, by Region, 2020-2034 (USD Billion)
5.9. Others
- 5.9.1. Global Cancer Biomarkers Market, by Others, by Region, 2020-2034 (USD Billion)

6. Global Cancer Biomarkers Market, by Biomolecule

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
6.3. Genetic Biomarkers
- 6.3.1. Global Cancer Biomarkers Market, by Genetic Biomarkers, by Region, 2020-2034 (USD Billion)
6.4. Epigenetic Biomarkers
- 6.4.1. Global Cancer Biomarkers Market, by Epigenetic Biomarkers, by Region, 2020-2034 (USD Billion)
6.5. Metabolic Biomarkers
- 6.5.1. Global Cancer Biomarkers Market, by Metabolic Biomarkers, by Region, 2020-2034 (USD Billion)
6.6. Proteomic Biomarkers
- 6.6.1. Global Cancer Biomarkers Market, by Proteomic Biomarkers, by Region, 2020-2034 (USD Billion)
6.7. Others
- 6.7.1. Global Cancer Biomarkers Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Cancer Biomarkers Market, by Application

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
7.3. Drug discovery & Development
- 7.3.1. Global Cancer Biomarkers Market, by Drug discovery & Development, by Region, 2020-2034 (USD Billion)
7.4. Diagnostics
- 7.4.1. Global Cancer Biomarkers Market, by Diagnostics, by Region, 2020-2034 (USD Billion)
7.5. Personalized medicine
- 7.5.1. Global Cancer Biomarkers Market, by Personalized medicine, by Region, 2020-2034 (USD Billion)
7.6. Others
- 7.6.1. Global Cancer Biomarkers Market, by Others, by Region, 2020-2034 (USD Billion)

8. Global Cancer Biomarkers Market, by Geography

8.1. Key Findings
8.2. Introduction
- 8.2.1. Cancer Biomarkers Market Assessment, By Geography, 2020-2034 (USD Billion)
8.3. Cancer Biomarkers Market - North America
- 8.3.1. North America: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
- 8.3.2. North America: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
- 8.3.3. North America: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.3.4. Cancer Biomarkers Market - U.S.
  - 8.3.4.1. U.S.: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.3.4.2. U.S.: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.3.4.3. U.S.: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.3.5. Cancer Biomarkers Market - Canada
  - 8.3.5.1. Canada: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.3.5.2. Canada: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.3.5.3. Canada: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
8.4. Cancer Biomarkers Market - Europe
- 8.4.1. Europe: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
- 8.4.2. Europe: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
- 8.4.3. Europe: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.4.4. Cancer Biomarkers Market - UK
  - 8.4.4.1. UK: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.4.4.2. UK: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.4.4.3. UK: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.4.5. Cancer Biomarkers Market - France
  - 8.4.5.1. France: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.4.5.2. France: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.4.5.3. France: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.4.6. Cancer Biomarkers Market - Germany
  - 8.4.6.1. Germany: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.4.6.2. Germany: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.4.6.3. Germany: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.4.7. Cancer Biomarkers Market - Italy
  - 8.4.7.1. Italy: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.4.7.2. Italy: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.4.7.3. Italy: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.4.8. Cancer Biomarkers Market - Spain
  - 8.4.8.1. Spain: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.4.8.2. Spain: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.4.8.3. Spain: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.4.9. Cancer Biomarkers Market - Netherlands
  - 8.4.9.1. Netherlands: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.4.9.2. Netherlands: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.4.9.3. Netherlands: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.4.10. Cancer Biomarkers Market - Russia
  - 8.4.10.1. Russia: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.4.10.2. Russia: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.4.10.3. Russia: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.4.11. Cancer Biomarkers Market - Rest of Europe
  - 8.4.11.1. Rest of Europe: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.4.11.2. Rest of Europe: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.4.11.3. Rest of Europe: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
8.5. Cancer Biomarkers Market - Asia Pacific
- 8.5.1. Asia Pacific: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
- 8.5.2. Asia Pacific: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
- 8.5.3. Asia Pacific: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.5.4. Cancer Biomarkers Market - China
  - 8.5.4.1. China: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.5.4.2. China: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.5.4.3. China: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.5.5. Cancer Biomarkers Market - India
  - 8.5.5.1. India: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.5.5.2. India: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.5.5.3. India: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.5.6. Cancer Biomarkers Market - Malaysia
  - 8.5.6.1. Malaysia: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.5.6.2. Malaysia: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.5.6.3. Malaysia: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.5.7. Cancer Biomarkers Market - Japan
  - 8.5.7.1. Japan: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.5.7.2. Japan: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.5.7.3. Japan: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.5.8. Cancer Biomarkers Market - Indonesia
  - 8.5.8.1. Indonesia: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.5.8.2. Indonesia: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.5.8.3. Indonesia: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.5.9. Cancer Biomarkers Market - South Korea
  - 8.5.9.1. South Korea: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.5.9.2. South Korea: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.5.9.3. South Korea: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.5.10. Cancer Biomarkers Market - Australia
  - 8.5.10.1. Australia: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.5.10.2. Australia: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.5.10.3. Australia: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.5.11. Cancer Biomarkers Market - Rest of Asia Pacific
  - 8.5.11.1. Rest of Asia Pacific: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.5.11.2. Rest of Asia Pacific: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.5.11.3. Rest of Asia Pacific: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
8.6. Cancer Biomarkers Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
- 8.6.2. Middle East & Africa: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
- 8.6.3. Middle East & Africa: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.6.4. Cancer Biomarkers Market - Saudi Arabia
  - 8.6.4.1. Saudi Arabia: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.6.4.2. Saudi Arabia: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.6.4.3. Saudi Arabia: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.6.5. Cancer Biomarkers Market - UAE
  - 8.6.5.1. UAE: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.6.5.2. UAE: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.6.5.3. UAE: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.6.6. Cancer Biomarkers Market - Israel
  - 8.6.6.1. Israel: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.6.6.2. Israel: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.6.6.3. Israel: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.6.7. Cancer Biomarkers Market - South Africa
  - 8.6.7.1. South Africa: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.6.7.2. South Africa: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.6.7.3. South Africa: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.6.8. Cancer Biomarkers Market - Rest of Middle East & Africa
  - 8.6.8.1. Rest of Middle East & Africa: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.6.8.2. Rest of Middle East & Africa: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.6.8.3. Rest of Middle East & Africa: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
8.7. Cancer Biomarkers Market - Latin America
- 8.7.1. Latin America: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
- 8.7.2. Latin America: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
- 8.7.3. Latin America: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.7.4. Cancer Biomarkers Market - Mexico
  - 8.7.4.1. Mexico: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.7.4.2. Mexico: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.7.4.3. Mexico: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.7.5. Cancer Biomarkers Market - Brazil
  - 8.7.5.1. Brazil: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.7.5.2. Brazil: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.7.5.3. Brazil: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.7.6. Cancer Biomarkers Market - Argentina
  - 8.7.6.1. Argentina: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.7.6.2. Argentina: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.7.6.3. Argentina: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)
- 8.7.7. Cancer Biomarkers Market - Rest of Latin America
  - 8.7.7.1. Rest of Latin America: Cancer Biomarkers Market, by Type, 2020-2034 (USD Billion)
  - 8.7.7.2. Rest of Latin America: Cancer Biomarkers Market, by Biomolecule, 2020-2034 (USD Billion)
  - 8.7.7.3. Rest of Latin America: Cancer Biomarkers Market, by Application, 2020-2034 (USD Billion)

9. Competitive Landscape

9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

10.1. Roche Diagnostics
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
10.2. Thermo Fisher Scientific
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
10.3. Abbott Laboratories
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
10.4. Qiagen N.V.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
10.5. Illumina, Inc.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
10.6. Bio-Rad Laboratories
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
10.7. Agilent Technologies
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
10.8. PerkinElmer, Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
10.9. Hologic, Inc.
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
10.10. Myriad Genetics, Inc.
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development